A multidisciplinary team of scientists at the Indian Institute of Science (IISc) successfully isolated a novel biological enzyme capable of breaking down stubborn antibiotic-resistant bacterial biofilms. The specialized protein enzyme, derived from bovine gut microbes, effectively degrades the protective matrix that pathogens produce to shield themselves from standard clinical treatments. By weakening this cellular defense barrier, the discovery enables existing antibiotic medications to penetrate and clear chronic bacterial infections at significantly lower dosage thresholds. Medical researchers emphasized that the enzyme-based approach offers a scalable pathway for developing next-generation antimicrobial therapies against critical drug-resistant hospital superbugs. Isolating Cow Gut Enzymes to Target Bacterial BiofilmsResearchers at the Indian Institute of Science (IISc), Bengaluru, have uncovered a novel therapeutic strategy to combat antimicrobial resistance (AMR) by isolating specialized enzymes from bovine rumen (cow gut) that dismantle the protective biofilm shields of drug-resistant superbugs. Published in npj Biofilms and Microbiomes, the study highlights an isolated enzyme named CRhAB (Cow rumen hydrolase against A. baumannii), which targets the complex polysaccharide matrices secreted by dangerous pathogens. Led by Associate Professor Debasis Das (Department of Inorganic and Physical Chemistry) and Professor Dipshikha Chakravortty (Department of Microbiology and Cell Biology), the team leveraged genomic data from cattle gut microbes—which naturally digest complex plant polysaccharides—to synthesize enzymes capable of digesting the structural sugar chains that shield bacterial colonies. Mechanism of Action and Targeted SuperbugsParameter / MetricScientific Details & FindingsPrimary Enzyme IsolatedCRhAB (Cow rumen hydrolase against A. baumannii)Key Target PathogensAcinetobacter baumannii & Klebsiella pneumoniae (WHO Critical Priority ESKAPE Group)Biofilm Composition TargetedPolysaccharide matrix (constituting 45%–95% of biofilm mass)MechanismWeakens physical matrix defenses without directly killing bacteria, preventing resistance evolutionTranslational DeliveryBioactive enzyme-infused wound gauze and proposed nebulizable/inhalable spraysDismantling Biofilm Defenses Without Driving ResistanceBacterial biofilms act as physical and biochemical barriers, rendering superbugs like Acinetobacter baumannii up to 1,000 times more resistant to conventional antibiotics and host immune cells. By digesting the polysaccharide framework that binds the biofilm together, CRhAB degrades matrix integrity and suppresses the expression of key biofilm-regulating genes without exerting direct selective pressure on the bacteria itself. This resistance-agnostic approach weakens bacterial defenses, allowing existing antibiotics to penetrate the colony and effectively neutralize the infection. The dual-action capability against both A. baumannii and Klebsiella pneumoniae offers a crucial unified mechanism against some of the most persistent hospital-acquired pathogens. Bioactive Gauze Applications and Future Respiratory FormulationsTo test practical medical applications, the IISc team engineered an enzyme-immobilized bioactive gauze designed for topical wound care. In preclinical mouse models, the CRhAB-coated dressing significantly reduced biofilm burden and accelerated wound healing when combined with standard antibiotic therapy. Building on these results, the researchers are developing patch-based dressings tailored for chronic diabetic foot ulcers, as well as investigating inhalable and nebulized enzyme formulations. Delivering CRhAB directly to lung tissues aims to prevent and disrupt established biofilms in complex respiratory tract infections, offering a major breakthrough in the global fight against drug-resistant superbugs. Dismantling Biofilm Defenses Without Driving Resistance Bacterial biofilms act as physical and biochemical barriers, rendering superbugs like Acinetobacter baumannii up to 1,000 times more resistant to conventional antibiotics and host immune cells. By digesting the polysaccharide framework that binds the biofilm together, CRhAB degrades matrix integrity and suppresses the expression of key biofilm-regulating genes without exerting direct selective pressure on the bacteria itself. This resistance-agnostic approach weakens bacterial defenses, allowing existing antibiotics to penetrate the colony and effectively neutralize the infection. The dual-action capability against both A. baumannii and Klebsiella pneumoniae offers a crucial unified mechanism against some of the most persistent hospital-acquired pathogens. Researchers at the Indian Institute of Science (IISc), Bengaluru, have uncovered a novel therapeutic strategy to combat antimicrobial resistance (AMR) by isolating specialized enzymes from bovine rumen (cow gut) that dismantle the protective biofilm shields of drug-resistant superbugs. Published in npj Biofilms and Microbiomes, the study highlights an isolated enzyme named CRhAB (Cow rumen hydrolase against A. baumannii), which targets the complex